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Abstract
The design and synthesis of dual aromatase inhibitors/selective estrogen receptor modulators (AI/
SERMs) is an attractive strategy for the discovery of new breast cancer therapeutic agents. 
Previous efforts led to the preparation of norendoxifen (4) derivatives with dual aromatase 
inhibitory activity and estrogen receptor binding activity. In the present study, some of the 
structural features of the potent AI letrozole were incorporated into the lead compound 
(norendoxifen) to afford a series of new dual AI/SERM agents based on a symmetrical 
diphenylmethylene substructure that eliminates the problem of E,Z isomerization encountered 
with norendoxifen-based AI/SERMs. Compound 12d had good aromatase inhibitory activity (IC50 
= 62.2 nM) while also exhibiting good binding activity to both ER-α (EC50 = 72.1 nM) and ER-β 
(EC50 = 70.8 nM). In addition, a new synthesis was devised for the preparation of norendoxifen 
and its analogues through a bis-Suzuki coupling strategy.
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2. Introduction
In spite of considerable therapeutic advances, breast cancer remains a significant public 
health problem.1 Estrogens play a prominent role in stimulating the growth and development 
of the majority of breast cancers.2, 3 Hence, estrogen receptors (ERs) are important targets 
for the development of new therapeutic agents for breast cancer treatment. Selective estrogen 
receptor modulators (SERMs), which were developed in the late 1950’s and early 1960’s, 
are widely used for the treatment of breast cancer.4 SERMs are able to bind to the estrogen 
receptors (ER-α and ER-β) in much the same way as estrogens do, and they block ERs in 
breast cancer cells in breast tissue while stimulating ERs in normal tissues.5 Tamoxifen (1) 
is a representative antagonist of the ERs in breast tissue and is the most commonly used 
SERM for the treatment of breast cancer (Figure 1). However, despite the fact that many 
patients benefit from tamoxifen, resistance to it often emerges, resulting in therapeutic 
failure.6, 7 Aromatase inhibitors (AIs), which prevent the formation of estradiol, were 
developed for the treatment of ER-positive breast cancer during the 1980’s.8 They have 
shown superior clinical efficacy compared to tamoxifen in postmenopausal breast cancer 
patients,8 and are considered as an alternative strategy for tamoxifen-resistant breast cancer. 
Unfortunately, the use of AIs is accompanied with significant side effects, including 
reduction of bone density, severe musculoskeletal pain, and increased frequency of fractures 
and cardiovascular events.9–12
Combination endocrine therapy has emerged as an effective cancer treatment paradigm.13 
Several clinical trials have revealed a significant benefit resulting from combination 
endocrine therapy involving administration of a SERM and an AI.14, 15 However, this 
approach has some drawbacks. For example, in the ATAC trial, the combination of 
anastrozole (an AI) and tamoxifen (a SERM) was less effective than anastrozole alone.16 
Moreover, a patient who takes a number of different drugs is at greater risk for side effects 
and drug interactions.
Dual AI/SERMs might be expected to be more effective than the conventional combination 
of tamoxifen and an AI. The ER blocking activity of a dual AI/SERM in cancer cells might 
act synergistically with the AI activity to inhibit cancer cell proliferation, while in normal 
tissues the ER stimulation of a dual AI/SERM would be expected to alleviate the side effects 
resulting from the global estrogen depletion caused by the AI activity of the dual AI/SERM. 
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This therapeutic hypothesis motivated the search for compounds that inhibit aromatase and 
bind to estrogen receptors. Norendoxifen (4, Figure 1) was found to be an active tamoxifen 
metabolite that binds to ERs and is also a potent AI,17, 18 and that discovery has provided a 
platform for the design and synthesis of dual AI/SERMs based on the structure of 
norendoxifen.18–20 Subsequent work proved that installation of a 4′-hydroxy group on 
norendoxifen to make the metabolite 5 increased potency vs. aromatase and the two estrogen 
receptors.19 More recently, it was determined that the aminoethoxy side chain of 
norendoxifen can be replaced by a phenolic hydroxyl group and the activity vs. all three 
receptors (AI, ER-α, and ER-β) maintained as long as the ethyl group is replaced by an 
imidazolylmethyl moiety (e.g. compound 6) that can coordinate to the iron of aromatases.20 
Initial attempts to install a 4′-amino group in norendoxifen derivatives led to mixed results 
that were generally disappointing with regard to simultaneous binding to all three 
receptors.20 In spite of that, the present investigation was launched in an attempt to 
simultaneously optimize activity against aromatase, ER-α, and ER-β by replacement of the 
hydroxyl groups of 4′-hydroxynorendoxifen (5) derivatives with amino groups or nitro 
groups and elimination of the 2′-aminoethyl moiety. The hypothesis was that activity against 
aromatase, ER-α, and ER-β could be maintained in aminated derivatives even in the absence 
of imidazole and aminoethyl functionality using a structure-based drug design approach that 
would take advantage of the known structures of the receptors.
Of the third generation AIs, letrozole is 2–5 fold more potent than anastrozole and 
exemestane in its inhibition of aromatase in noncellular systems and 10–20 fold more potent 
in cellular systems (Figure 2).21 The structure of letrozole consists of two pharmacophores. 
One is the triazole ring. The other is the symmetrically substituted diphenylmethane 
fragment that has two identical substituents incorporated at the 4- and 4′-positions. The 
incorporation of a basic nitrogen and a symmetrically substituted diphenylmethane fragment 
into norendoxifen analogues might therefore provide an approach to optimize aromatase 
inhibition (Figure 3). Therefore, norendoxifen was modified by the removal of the 
aminoethoxyl side chain and introduction of a nitro or amino group in the para position of 
the “A” ring (Figure 3). The resulting compounds have no geometrical isomers and, similar 
to anastrozole and letrozole, they also incorporate hydrogen bond acceptors.
3. Results and Discussion
3.1 Synthesis and Evaluation of Triphenylethylenes 12a–d
The importance of the nitro group as an H-bond acceptor in potent and selective AIs has 
been emphasized previously by Gobbi and co-workers.22 Initial attempts were made to 
synthesize the desired nitrated triphenylethylenes 12 by McMurry coupling of 
benzophenones with propiophenones using the methodology previously reported by our 
group and others.23–25 However, when 4-nitroacetophenone 10a was treated with 4,4′-
dihydroxybenzophenone 11 in dry THF in the presence of TiCl4 and Zn, none of the desired 
McMurry product 12a was observed (Scheme 1). Attempts to use BOC-protected 4-
aminoacetophenone in place of 4-nitroacetophenone 10a were uniformly unsuccessful.
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The failure of the McMurry approach led to another strategy to transform 10a into 12a, 
namely conversion of ketone 10a into a 1,1-dibromo-1-alkene 14a before performing 
palladium-catalyzed coupling reactions.26, 27 Subsequent coupling of 14a with 4-
hydroxyphenylboronic acid under Suzuki conditions proceeded smoothly to provide the 
desired product 12a in good yield (67%) (Scheme 2).
The analogues 12b–d were prepared by employing the same strategy as that used for the 
synthesis of compound 12a (Scheme 2). The nitro-substituted ketones 10a and 10b were 
initially treated with hydrazine hydrate at reflux in EtOH to provide the hydrazones 13a and 
13b in 85% and 90% yields, respectively.26 The hydrazones 13a and 13b were reacted with 
CBr4 in the presence of CuCl to provide the 1,1-dibromo-1-alkenes 14a and 14b in 65% and 
50% yields, respectively.27 Finally, the bis-Suzuki arylation of 14a and 14b with 4-
hydroxyphenylboronic acid or 4-aminophenylboronic acid in the presence of PdCl2(PPh3)2 
at 70 ºC in THF-H2O resulted in the formation of 12a–d in 47–57% yields.
Compounds 12a–d were evaluated for their aromatase inhibitory activities and ER binding 
affinities (Table 1). The IC50 and EC50 values for the previously reported compounds 13, 
(E,Z)-norendoxifen, (E)-norendoxifen, and (Z)-norendoxifen are included for comparison.18 
The results indicate that nitro-substituted bis-phenol compounds 12a and 12b are very weak 
AIs with 75% and 78% inhibition at 50 μM, respectively. However, the aniline-type 
compounds 12c and 12d exhibited remarkably improved inhibitory activity against 
aromatase and affinity for ER-α and ER-β when compared with the unsubstituted derivative 
13 and with the phenols 12a and 12b. They were 113 and 400 times more potent than 13 
against aromatase (IC50 220.8 and 62.2 vs 24880 nM), respectively. Compound 12d showed 
slightly improved aromatase inhibitory activity and slightly decreased binding affinity to 
both ER-α and ER-β when compared with the lead compound (E,Z-norendoxifen). These 
results indicate that the replacement of the two phenols of 13 with amino groups and the 
introduction of a p-nitro group in the A-ring contribute in a positive way to both aromatase 
inhibition and ER binding affinity. Another conclusion that can be drawn is that the 
aminoethoxyl side chain is important for the hydroxyl-substituted norendoxifen analogues to 
retain optimal ER binding affinity and aromatase inhibitory activity, but it is not an essential 
requirement for amino-substituted analogues.
Molecular modeling was performed in order to investigate the binding mode of 12d in the 
active sites of aromatase and ER-α. The dianiline 12d was docked in the active sites of 
aromatase (PDB code 3s7928) and ER-α (PDB code 3ert29) using GOLD 3.0. These studies 
capitalized on the secure molecular modeling foundation established by previous 
investigations of the binding of (E)-norendoxifen and several analogues to both aromatase 
and ER-α, which involved GOLD 3.0 docking, Amber 10 molecular dynamics simulations 
and Amber parm99 energy minimizations, as well as MM-PBSA binding energy 
calculations 18–20 The calculated models were consistent with experimentally determined 
SAR. As shown in Figure 4, the overall pose of the ligand is close to that present in the 
previously published models of (E)-norendoxifen and its analogues bound to 
aromatase.18–20 The amino group on the aniline ring that is trans to the nitrophenyl ring 
hydrogen bonds to the backbone carbonyl of Asp309. In common with the present situation, 
all of the previously published models involve hydrogen bonding to Asp309. However, the 
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present model is different in that the amino group on the aniline ring that is cis to the 
nitrophenyl does not hydrogen bond to backbone carbonyl of Leu372. This may be related to 
the fact that all of the previously modeled compounds were phenols instead of anilines.
The molecular model calculated for the binding of 12d to ER-α is displayed in Figure 5. In 
this case, the amino group on the phenyl ring that is cis to the nitrophenyl ring hydrogen 
bonds to the hydroxyl of Thr347 while the other amino group hydrogen bonds to the 
carboxylate of Glu353 and the backbone carbonyl of Phe404. The overall pose and the 
involvement of Thr347 and Glu353 are similar to that in the previously published model of 
(Z)-norendoxifen and one of its analogues bound to ER-α.20 On the other hand, the present 
case differs in the hydrogen bonding to Phe404 instead of Arg394.20
3.2 Synthesis and Evaluation of Triphenylethylenes 15a–d
The encouraging findings for 12c and 12d reported in Table 1 led to the preparation of 
compounds 15a–d to explore the effect of replacing the “A” ring nitro group with an amino 
group as shown in Scheme 3. Compounds 15a–d were easily obtained in 52–80% yield by 
reduction of the corresponding nitrosubstituted triphenylalkenes 12a–d with SnCl2 (Scheme 
3).
The biological results for compounds 15a–d are summarized in Table 2. Replacement of the 
nitro groups in 12a–d with amino groups produced mixed results on the binding affinity 
with the ERs while all four amino compounds showed significantly improved inhibitory 
activity against aromatase. In particular, compound 15b was the most potent of the AIs 
synthesized in this project with an IC50 value of 8.8 nM, which is close to the widely 
prescribed AI letrozole (IC50 = 5.3 nM30). These results clearly demonstrate the important 
role played by the “A” ring amino group in 15b and 15d in increasing the aromatase 
inhibitory activity compared to norendoxifen, the nitro derivatives 12b and 12d, and 
unsubstituted compound 13.
Comparing 15b with 15a reveals a significant increase in potency on aromatase from IC50 
230 to 8.8 nM and from 11036 to 1711 nM in affinity to ER-α. A similar effect on 
aromatase was observed for compounds 15c and 15d. Obviously, the ethyl substituent is 
better than the methyl when tested on aromatase and ER-α, but it is actually slightly worse 
vs. ER-β when comparing 15a to 15b.
3.3 Synthesis and Evaluation of Triphenylethylenes 16a–d
Compounds 16a–d were prepared in 30–56% yield by treatment of 12a–d with one 
equivalent of 2-iodoacetamide in the presence of K2CO3 (Scheme 4). This allows 
comparison of two sets 16a–d and 12a–d with respect to ER binding affinity and aromatase 
inhibition to determine the effect of the amide side chain on the dual interaction.
The biological testing results for compounds 16a–d are summarized in Table 3. IC50 and 
EC50 values for the previously reported amide 17 are included for comparison.18 
Substitution of the amino group in one of the phenyl rings of 12c with the amide side chain 
in 16c decreased aromatase inhibitory activity (IC50 220.8 vs 645.3 nM). Compound 16d 
also exhibited decreased aromatase inhibitory activity when compared with 12d (IC50 286.9 
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vs 62.2 nM). Compounds 16c and 16d exhibited elevated potency against both aromatase 
and ER when compared with 16a, 16b, and 17. The presence of the side chain produced 
mixed results on the estrogen receptors. It increased affinity when installed on 12c (compare 
ER results for 12c and 16c), but it decreased affinity when installed on 12d (compare ER 
results for 12d and 16d).
3.4 Evaluation of Antiestrogenic Effects in a Functional, Cellular Assay
In order to gain information about the behavior of the triphenylethylenes beyond that 
provided by estrogen receptor affinity studies, compounds 12c, 12d, 16c, and 16d (1 μM) 
were tested in a functional assay that measured their abilities to block the effects of β-
estradiol (10 nM) in MCF-7 human breast cancer cells. These substances were selected for 
biological testing because of their relatively high affinity for ER-α and ER-β, and their 
potencies as estradiol antagonists were compared with endoxifen and (E,Z)-norendoxifen. 
The assay measures progesterone receptor (PGR) mRNA expression level, and the results of 
the assay are provided in Figure 6. β-Estradiol (10 nM) increased PGR mRNA expression to 
a level that was assigned the 100% value. Despite the fact that the affinities for ER-α ranged 
from 451.2 nM (16d) to 72.1 nM (12d) and those for ER-β ranged from 486.2 nM (12c) to 
70.8 nM (12d), the % RNA expression levels only ranged from 14% (16c) to 20% (12c) in 
the functional cellular assay, and the most potent compound in the functional assay (16c) 
was not one with the highest affinity for ER-α and ER-β (12d was). Endoxifen, the positive 
control, was able to antagonize PGR mRNA expression in the presence of 10 nM estradiol 
(E2) to the level of 3.5%, while the level of expression in the presence of (E,Z)-norendoxifen 
was 22%. These results are generally consistent with those previously reported for 
structurally related compounds.19, 20, 31, 32
These data indicate that each of the four compounds effectively inhibited the PGR 
expression. Future dose response studies will be required to determine if there are 
differences in potencies toward inhibiting the PGR expression or cell proliferation. Since the 
affinities for the two estrogen receptors varied quite similarly across the compounds, it will 
be interesting to determine their effects on cell proliferation in light of the studies showing 
that ER-α and ER-β have opposing effects on breast cancer cells in vitro.33
3.5 A New Synthesis of (E,Z)-Norendoxifen
Although the first synthesis of (E,Z)-norendoxifen through the McMurry reaction was 
recently reported, the method has limited applicability for the direct synthesis of 
hydroxylated, nitro, and amino derivatives.18 A new synthesis of (E,Z)-norendoxifen was 
therefore explored as an extension of the present work (Scheme 5). The synthesis of the 
triphenylalkene framework commenced with the condensation of propiophenone 18 with 
hydrazine hydrate in EtOH at reflux to provide the hydrazone 19 in excellent yield (88%).34 
1-(1,1-Dibromobut-1-en-2-yl)benzene 20 was prepared by reaction of hydrazone 19 with 
CBr4 (3.0 equiv) in the presence of CuCl (10 mol%) in DMSO in 70% yield.27 The bis-
Suzuki arylation of 20 with 4-hydroxyphenylboronic acid in the presence of PdCl2(PPh3)2 
(10 mol%) at 70 ºC in THF-H2O resulted in the formation of diphenol 13 in 52% yield. The 
diphenol 13 was treated with K2CO3 and 2-iodoacetamide (1.1 equiv) to afford the amide 17 
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as the major product in 32% yield. Finally, the reduction of the amide 17 using LiAlH4 
resulted in the generation of (E,Z)-norendoxifen in 64% yield.
4. Conclusion
A series of novel triphenylethylene derivatives based on a symmetrical diphenylmethylene 
template were designed and synthesized using a new Suzuki bis-arylation approach on an 
α,α-dibromoalkene. This circumvented problems encountered when the McMurry approach 
was tried. The para position of the “A” ring of these compounds was substituted with a nitro 
group or an amino group, while the para position of the “B” and “C” ring was substituted 
with a hydroxyl group or an amino group. SAR studies demonstrated that the aminoethoxyl 
side chain is not an essential requirement for tamoxifen (1) analogues to elicit both 
aromatase inhibitory and ER binding activity despite the fact that many previous reports 
have argued that it is important for the activity.35–39 The introduction of a para-amino group 
into the A-ring of the triphenylethylene scaffold led to a remarkable improvement of 
aromatase inhibitory activity (IC50 24880 nM for 13 vs. 8.8 nM for 15b).
Progress toward the goal to find new classes of AI/SERMs with favorable aromatase 
inhibitory activity and affinity to ER-α and ER-β was realized with dianiline 12d, which had 
potent aromatase inhibitory activity (IC50 = 62.2 nM) while also exhibiting high affinity to 
both ER-α (EC50 = 72.1 nM) and ER-β (EC50 = 70.8 nM). Moreover, compounds 15b 
(IC50 = 8.8 nM) and 15d (IC50 = 13.4 nM) displayed highly potent aromatase inhibitory 
activity that was close to that of the marketed drug letrozole (IC50 5.3 nM) while having low 
affinity for ER-α and ER-β.
The following conclusions about the structure-activity relationships were drawn: (1) The 
amino groups in the para positions of the “A” ring and “B” ring play key roles in the 
modulation of the aromatase inhibitory activity. (2) The unsymmetrical diphenylmethylene 
substructure of norendoxifen can be replaced by a symmetrical diphenylmethylene 
substructure, thereby eliminating E,Z-isomers of the triphenylethylenes and maintaining 
activity. (3) The replacement of ethyl side chain with a methyl group produced a negative 
result, whether for aromatase inhibition or ER binding affinity. (4) The aminoethoxyl side 
chain in triphenylalkene derivatives is not an essential requirement for optimal interaction 
with the estrogen receptors and aromatase.
Because of their promising biological activities and no complications arising from the 
presence of E,Z isomers, the present molecules based on a symmetrical diphenylmethylene 
template are suitable candidates for further development toward dual AI/SERMs for breast 
cancer treatment.
5. Experimental Section
5.1 Chemistry
Melting points were determined using capillary tubes with a Mel-Temp apparatus and are 
uncorrected. Reaction products were obtained in pure form directly from reaction mixtures 
or after column chromatography and did not require additional recrystallization. 1H NMR 
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and 13C NMR spectra were recorded using a Bruker ARX300 300 MHz spectrometer or a 
Bruker DPX 400 MHz spectrometer with TMS as internal standard. High-resolution mass 
spectra (HRMS) were recorded on a double-focusing sector mass spectrometer with 
magnetic and electrostatic mass analyzers or a Bruker microTOF Q spectrometer. 
Compound purities were estimated by reversed phase C18 high pressure liquid 
chromatography (HPLC) with UV detection at 254 nm. The major peak area of each 
biologically tested compound was ≥95% of the combined total peak area. Cytochrome P450 
(CYP) inhibitor screening kits for aromatase (CYP19) inhibition studies were purchased 
from BD Biosciences (San Jose, CA). ER α and β competitor assay kits were purchased 
from Invitrogen (Carlsbad, CA).
5.1.1 General Procedure for the Synthesis of Hydrazones (13a and 13b)26—A 
98% hydrazine monohydrate solution (1 mL, 20 mmol) was added to a suspension of ketone 
10a or 10b (10 mmol) in EtOH (10 mL). The mixture was heated to reflux for 2 h. After 
cooling to room temperature, the solid was filtered and the crude hydrazone was washed 
with H2O (20 mL X 2) and dried in vacuo. The product was used in the next step without 
further purification.
5.1.2 1-[1-(4-Nitrophenyl)ethylidene]hydrazine (13a)—Brick red solid, 85% yield, 
mp 149–150 °C (lit.26 mp 148–149 °C).
5.1.3 1-(1-(4-Nitrophenyl)propylidene)hydrazine (13b)—Orange crystalline solid, 
90% yield, mp 103–104 °C. 1H NMR (300 MHz, CDCl3) δ 8.18 (d, J = 7.1 Hz, 2 H), 7.80 
(d, J = 7.1 Hz, 2 H), 5.73 (s, 2 H), 2.64 (q, J = 7.7 Hz, 2 H), 1.18 (t, J = 7.7 Hz, 3 H); 13C 
NMR (75 MHz, CDCl3) δ 147.9, 146.2, 144.4, 125.8, 123.6, 17.9, 9.44; CIMS m/z 194 
(MH+); HRCIMS m/z calcd for C9H12N3O2 (MH+) 194.0924, found 194.0932.
5.1.4 General Procedure for the Synthesis of 1,1-Dibromo-1-alkenes (14a and 
14b)27—A 28% aqueous solution of ammonia (1 mL) and CuCl (0.3 mmol) were added to 
a solution of hydrazones 13a or 13b (3.0 mmol) in DMSO (3 mL). Then CBr4 (9 mmol) in 
DMSO (5 mL) was added dropwise. The reaction mixture was stirred at room temperature 
for 16 h and quenched with H2O (30 mL) and extracted with CH2Cl2 (20 mL X 3). After 
being dried over Na2SO4, the CH2Cl2 was evaporated and the residue was purified by 
column chromatography (hexane: EtOAc = 2: 1) to afford the product 14a or 14b.
5.1.5 1-(1,1-Dibromoprop-1-en-2-yl)-4-nitrobenzene (14a)—White solid, 65% yield, 
mp 81–82 °C. 1H NMR (300 MHz, CDCl3) δ 8.23 (d, J = 8.7 Hz, 2 H), 7.41 (d, J = 8.7 Hz, 
2 H), 2.23 (s, 1 H); 13C NMR (75 MHz, CDCl3) δ 148.5, 141.1, 128.6, 123.8, 123.4, 89.6, 
25.9; CIMS m/z 321 (MH+).
5.1.6 1-(1,1-Dibromobut-1-en-2-yl)-4-nitrobenzene (14b)—White solid, 50% yield: 
mp 57–58 °C. 1H NMR (300 MHz, CDCl3) δ 8.24 (d, J = 8.7 Hz, 2 H), 7.37 (d, J = 8.7 Hz, 
2 H), 2.63 (q, J = 7.5 Hz, 2 H), 0.98 (t, J = 7.4 Hz, 3 H); 13C NMR (75 MHz, CDCl3) δ 
147.5, 147.0, 146.9, 129.0, 123.8, 89.3, 32.6, 11.3; CIMS m/z 336 (MH+); HRCIMS m/z 
calcd for C10H10N1O279Br81Br (MH+) 335.9052, found 335.9048.
Zhao et al. Page 8
Bioorg Med Chem. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5.1.7 General Procedure for the Synthesis of Triphenylalkenes (12a–d)—A 
solution of 1,1-dibromo-1-alkenes 14a or 14b (1.0 mmol), 4-hydroxyphenylboronic acid or 
4-aminophenylboronic acid (4.0 mmol), PdCl2(PPh3)2 (0.1 mmol), and Na2CO3 (3.0 mmol) 
in THF-H2O (15 mL) was heated to 70 °C under Ar2 for 18 h. After cooling to room 
temperature, EtOAc (15 mL) and H2O (10 mL) were poured into the reaction mixture. The 
aqueous layer was extracted with EtOAc (20 mL X 3). The combined organic layers were 
washed with water and dried, concentrated in vacuo and purified by flash column 
chromatography (hexane: EtOAc = 2:1) to afford the products 12a–d.
5.1.8 4-(1-(4-Hydroxyphenyl)-2-(4-nitrophenyl)prop-1-enyl)phenol (12a)—Light 
brown solid, 67% yield: mp 235–236 °C. 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 9.0 Hz, 
2 H), 7.28 (d, J = 7.8 Hz, 2 H), 7.10 (d, J = 8.1 Hz, 2 H), 6.82 (d, J = 8.7 Hz, 2 H), 6.72 (d, J 
= 9.0 Hz, 2 H), 6.52 (d, J = 8.4 Hz, 2 H), 4.78 (s, 1 H), 4.62 (s, 1 H), 2.17 (s, 3 H); 13C NMR 
(75 MHz, CDCl3) δ 154.7, 154.3, 152.1, 145.5, 141.3, 135.2, 134.9, 132.3, 132.1, 131.3, 
130.2, 123.2, 115.0, 114.7, 22.9; ESIMS m/z 370 (MNa+); HRESIMS m/z calcd for 
C21H17NO4Na (MNa+) 370.1055, found 370.1066; HPLC purity, 100% (90% MeOH, 10% 
H2O).
5.1.9 4-(1-(4-Hydroxyphenyl)-2-(4-nitrophenyl)but-1-enyl)phenol (12b)—Pale 
yellow solid, 57% yield: mp 111–112 °C. 1H NMR (300 MHz, methanol-d4) δ 7.99 (d, J = 
8.7 Hz, 2 H), 7.29 (d, J = 8.7 Hz, 2 H), 7.03 (d, J = 8.7 Hz, 2 H), 6.77 (d, J = 8.1 Hz, 2 H), 
6.66 (d, J = 8.4 Hz, 2 H), 6.62 (s, 2 H), 6.44 (d, J = 9.0 Hz, 2 H), 2.54 (q, J = 7.8 Hz, 2 H), 
0.90 (t, J = 7.8 Hz, 3 H); 13C NMR (75 MHz, methanol-d4) δ 157.7, 157.1, 152.3, 147.1, 
142.8, 139.6, 135.7, 135.3, 133.3, 132.0, 131.6, 128.5, 124.0, 116.8, 116.5, 115.9, 115.5, 
29.5, 14.0; negative ion ESIMS m/z 360 (M – H+)−; negative ion HRESIMS m/z calcd for 
C22H18NO4 (M – H+)− 360.1236, found 360.1237; HPLC purity, 95.18% (90% MeOH, 10% 
H2O).
5.1.10 4-(1-(4-Aminophenyl)-2-(4-nitrophenyl)prop-1-enyl)benzenamine (12c)—
Brick red solid, 55% yield: mp 202–204 °C. 1H NMR (300 MHz, methanol-d4) δ 7.97 (d, J 
= 6.6 Hz, 2 H), 7.32 (d, J = 7.2 Hz, 2 H), 6.96 (d, J = 6.9 Hz, 2 H), 6.71 (d, J = 6.9 Hz, 2 H), 
6.60 (d, J = 6.6 Hz, 2 H), 6.41 (d, J = 6.9 Hz, 2 H), 2.16 (s, 3 H); 13C NMR (75 MHz, 
methanol-d4) δ 154.3, 147.4, 146.8, 144.1, 134.4, 133.2, 132.0, 131.8, 131.6, 124.0, 116.2, 
115.9, 23.0; ESIMS m/z 346 (MH+); HRESIMS m/z calcd for C21H20N3O2 (MH+) 
346.1556, found 346.1572; HPLC purity, 100% (90% MeOH, 10% H2O).
5.1.11 4-(1-(4-Aminophenyl)-2-(4-nitrophenyl)but-1-enyl)benzenamine (12d)—
Brick red solid, 40% yield: mp 182–183 °C. 1H NMR (300 MHz, methanol-d4) δ 7.99 (d, J 
= 8.7 Hz, 2 H), 7.32 (d, J = 8.7 Hz, 2 H), 6.95 (d, J = 9.0 Hz, 2 H), 6.70 (d, J = 8.4 Hz, 2 H), 
6.57 (d, J = 9.0 Hz, 2 H), 6.38 (d, J = 8.4 Hz, 2 H), 2.58 (q, J = 7.8 Hz, 2 H), 0.92 (t, J = 7.5 
Hz, 3 H); 13C NMR (75 MHz, methanol-d4) δ 152.9, 147.9, 143.7, 138.6, 134.1, 133.1, 
132.1, 131.4, 124.0, 116.1, 115.6, 29.5, 14.0; ESIMS m/z 360 (MH+); HRESIMS m/z calcd 
for C22H22N3O2 (MH+) 360.1712, found 360.1723; HPLC purity, 97.74% (90% MeOH, 
10% H2O).
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5.1.12 General Procedure for the Synthesis of Reduction Products (15a–d)—A 
solution of nitro-containing compounds 12a or 12b or 12c or 12d (0.3 mmol) and SnCl2 (1.5 
mmol) in ethanol (10 mL) was heated at reflux for 5 h. After the reaction mixture was 
cooled to room temperature, saturated aq K2CO3 solution was slowly added with stirring 
until the pH was 8–9. Then the mixture was extracted with EtOAc (10 mL X 3), and the 
combined organic layer was dried. The solvent was evaporated and the residue was purified 
by flash column chromatography (EtOAc: hexane = 1:1) to afford the products 15a–d.
5.1.13 4-(2-(4-Aminophenyl)-1-(4-hydroxyphenyl)prop-1-enyl)phenol (15a)—
White solid, 80% yield: mp 154–156 °C. 1H NMR (300 MHz, DMSO-d6) δ 9.34 (s, 1 H), 
9.12 (s, 1 H), 6.91 (d, J = 8.5 Hz, 2 H), 6.75 (d, J = 8.5 Hz, 2 H), 6.70 (d, J = 8.5 Hz, 2 H), 
6.60 (d, J = 8.5 Hz, 2 H), 6.42 (d, J = 8.5 Hz, 2 H), 6.32 (d, J = 8.5 Hz, 2 H), 4.97 (s, 2 H), 
1.95 (s, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 156.5, 155.8, 147.4, 137.4, 135.7, 133.7, 
132.4, 132.2, 131.7, 130.6, 115.7, 115.2, 114.3, 23.9; MALDIMS m/z 317 (M+); HRESIMS 
m/z calcd for C21H20NO2 (MH+) 318.1494, found 318.1495; HPLC purity, 97.85% (90% 
MeOH, 10% H2O).
5.1.14 4-(2-(4-Aminophenyl)-1-(4-hydroxyphenyl)but-1-enyl)phenol (15b)—
White solid, 71% yield: mp 173–175 °C. 1H NMR (300 MHz, DMSO-d6) δ 9.34 (s, 1 H), 
9.10 (s, 1 H), 6.93 (d, J = 8.5 Hz, 2 H), 6.72 (d, J = 8.5 Hz, 2 H), 6.59 (d, J = 8.5 Hz, 2 H), 
6.40 (d, J = 8.5 Hz, 2 H), 6.37 (d, J = 8.5 Hz, 2 H), 6.34 (d, J = 8.5 Hz, 2 H), 4.92 (s, 2 H), 
2.30 (q, J = 7.4 Hz, 2 H), 0.84 (t, J = 7.4 Hz, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 156.7, 
155.7, 147.4, 137.7, 135.8, 135.2, 134.9, 132.3, 131.1, 130.8, 115.8, 115.1, 114.5, 29.3, 
14.7; MALDIMS m/z 331 (M+); HRESIMS m/z calcd for C22H22NO2 (MH+) 332.1651, 
found 332.1651; HPLC purity, 99.59% (90% MeOH, 10% H2O).
5.1.15 4-(1,2-Bis(4-aminophenyl)prop-1-enyl)benzenamine (15c)—White solid, 
52% yield: mp 134–135 °C. 1H NMR (300 MHz, DMSO-d6) δ 6.77 (d, J = 8.3 Hz, 2 H), 
6.75 (d, J = 8.3 Hz, 2 H), 6.49 (d, J = 8.1 Hz, 2 H), 6.40 (d, J = 8.2 Hz, 2 H), 6.32 (d, J = 8.4 
Hz, 2 H), 6.21 (d, J = 8.4 Hz, 2 H), 4.88 (s, 6 H), 1.96 (s, 3 H); 13C NMR (75 MHz, DMSO-
d6) δ 147.7, 147.1, 146.9, 138.4, 132.9, 132.2, 131.6, 131.4, 130.6, 114.3, 113.9, 24.1; 
MALDIMS m/z 315 (M+); HRESIMS m/z calcd for C21H22N3 (MH+) 316.1814, found 
316.1814; HPLC purity, 95.50% (90% MeOH, 10% H2O).
5.1.16 4-(1,2-Bis(4-aminophenyl)but-1-enyl)benzenamine (15d)—White solid, 
56% yield: mp 145–147 °C. 1H NMR (300 MHz, DMSO-d6) δ 6.77 (d, J = 8.3 Hz, 2 H), 
6.73 (d, J = 8.3 Hz, 2 H), 6.49 (d, J = 8.3 Hz, 2 H), 6.45 (d, J = 8.4 Hz, 2 H), 6.34 (d, J = 8.3 
Hz, 2 H), 6.20 (d, J = 8.4 Hz, 2 H), 4.89 (s, 6 H), 2.33 (q, J = 7.4 Hz, 2 H), 0.83 (t, J = 7.2 
Hz, 3 H); 13C NMR (75 MHz, DMSO-d6) δ 147.7, 147.1, 146.7, 138.6, 133.1, 132.8, 132.1, 
131.0, 130.8, 130.7, 129.8, 129.1, 114.5, 114.4, 113.9, 29.2, 14.8; MALDINS m/z 329 (M+); 
HRESIMS m/z calcd for C22H24N3 (MH+) 330.1970, found 330.1971; HPLC purity, 
96.91% (90% MeOH, 10% H2O).
5.1.17 General Procedure for the Synthesis of the Monoalkylated Products 
(16a–d)—A suspension of the diphenols 12a or 12b or dianilines 12c or 12d (1 mmol) and 
K2CO3 (3 mmol) in acetone (10 mL) was heated at reflux for 10 min. A solution of 2-
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iodoacetamide (1.3 mmol) in acetone (6 mL) was added in small portions over 3 h and the 
reaction mixture was heated at reflux for an additional 1 h. After cooling to room 
temperature, the solvent was evaporated and the residue was dissolved in saturated NH4Cl 
solution (30 mL) and extracted with EtOAc (30 mL X 3). The organic layers were 
combined, dried, concentrated in vacuo and purified by flash column chromatography to 
provide the products 16a–d.
5.1.18 (E,Z)-2-(4-(1-(4-Hydroxyphenyl)-2-(4-nitrophenyl)prop-1-enyl)phenoxy)-
acetamide (16a)—Yellow solid, 41% yield: mp 129–130 °C. 1H NMR (300 MHz, 
methanol-d4) δ 7.99 (d, J = 9.3 Hz, 2 H, isomer 1), 7.98 (d, J = 8.7 Hz, 2 H, isomer 2), 7.34 
(d, J = 9.3 Hz, 2 H, isomer 1), 7.33 (d, J = 8.7 Hz, 2 H, isomer 2), 7.17 (d, J = 8.7 Hz, 2 H, 
isomer 2), 7.02 (d, J = 8.4 Hz, 2 H, isomer 1), 6.98 (d, J = 8.0 Hz, 2 H, isomer 1), 6.82-6.76 
(m, 4 H), 6.66 (d, J = 8.7 Hz, 4 H), 6.46 (d, J = 8.7 Hz, 2 H, isomer 2), 4.51 (s, 2 H, isomer 
1), 4.53 (s, 2 H, isomer 2), 2.15 (s, 3 H, isomer 1), 2.13 (s, 3 H, isomer 2); 13C NMR (75 
MHz, methanol-d4) δ 174.0, 174.0, 158.2, 157.8, 157.7, 157.4, 153.5, 147.1, 142.8, 137.9, 
137.7, 135.2, 135.0, 133.8, 133.6, 133.3, 133.3, 133.1, 132.3, 132.2, 131.6, 124.1, 116.0, 
115.6, 115.5, 115.0, 67.9, 67.8, 23.2, 23.0; negative ion ESIMS m/z 403 (M – H+)−; 
HRESIMS m/z calcd for C23H21N2O5 (MH+) 405.1450, found 405.1460; HPLC purity, 
95.55% (90% MeOH, 10% H2O).
5.1.19 (E,Z)-2-(4-(1-(4-Hydroxyphenyl)-2-(4-nitrophenyl)but-1-enyl)phenoxy)-
acetamide (16b)—Yellow oil, 56% yield. 1H NMR (300 MHz, methanol-d4) δ 8.01 (d, J 
= 8.7 Hz, 2 H, isomer 1), 8.00 (d, J = 8.7 Hz, 2 H, isomer 2), 7.32 (d, J = 8.7 Hz, 2 H, isomer 
1), 7.31 (d, J = 8.7 Hz, 2 H, isomer 2), 7.15 (d, J = 8.7 Hz, 2 H, isomer 2), 7.00 (d, J = 8.4 
Hz, 2 H, isomer 1), 6.97 (d, J = 8.0 Hz, 2 H, isomer 1), 6.79-6.76 (m, 4 H), 6.64 (d, J = 8.7 
Hz, 4 H), 6.44 (d, J = 8.7 Hz, 2 H, isomer 2), 4.51 (s, 2 H, isomer 1), 4.34 (s, 2 H, isomer 2), 
2.59-2.50 (m, 4 H), 0.94-0.89 (m, 6 H); 13C NMR (75 MHz, methanol-d4) δ 174.1, 158.2, 
157.8, 157.2, 152.0, 147.2, 142.2, 140.5, 140.2, 137.9, 137.6, 135.3, 135.0, 133.3, 133.2, 
132.1, 131.7, 131.6, 124.1, 116.0, 115.6, 115.0, 68.0 67.8, 29.6, 29.5, 13.9; ESIMS m/z 441 
(MNa+); HRESIMS m/z calcd for C24H22N2O5Na (MNa+) 441.1427, found 441.1431; 
HPLC purity, 97.18% (90% MeOH, 10% H2O).
5.1.20 (E,Z)-2-(4-(1-(4-Aminophenyl)-2-(4-nitrophenyl)prop-1-
enyl)phenylamino)acetamide (16c)—Reddish-brown solid, 30% yield: mp 112–
114 °C. 1H NMR (300 MHz, methanol-d4) δ 7.98 (d, J = 8.8 Hz, 2 H, isomer 1), 7.97 (d, J = 
8.8 Hz, 2 H, isomer 2), 7.33 (d, J = 8.7 Hz, 2 H, isomer 1), 7.32 (d, J = 8.7 Hz, 2 H, isomer 
2), 6.97 (d, J = 8.4 Hz, 2 H, isomer 1), 6.95 (d, J = 8.4 Hz, 2 H, isomer 2), 6.70 (d, J = 8.5 
Hz, 2 H, isomer 1), 6.65-6.58 (m, 6 H), 6.41 (d, J = 8.5 Hz, 2 H), 6.28 (d, J = 8.5 Hz, 2 H), 
3.94 (s, 2 H, isomer 1), 3.75 (s, 2 H, isomer 2), 2.15 (s, 6 H); 13C NMR (75 MHz, methanol-
d4) δ 177.1, 154.3, 148.3, 148.0, 146.8, 134.7, 133.9, 133.2, 132.1, 132.0, 131.7, 124.0, 
116.1, 115.9, 113.3, 112.9, 23.1; ESIMS m/z 425 (MNa+); HRESIMS m/z calcd for 
C23H23N4O3 (MH+) 403.1770, found 403.1776; HPLC purity, 97.57% (90% MeOH, 10% 
H2O).
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5.1.21 (E,Z)-2-(4-(1-(4-Aminophenyl)-2-(4-nitrophenyl)but-1-
enyl)phenylamino)acetamide (16d)—Reddish-brown solid, 34% yield: mp 132–
135 °C. 1H NMR (300 MHz, methanol-d4) δ 7.99 (d, J = 8.8 Hz, 2 H, isomer 1), 7.98 (d, J = 
8.8 Hz, 2 H, isomer 2), 7.32 (d, J = 8.7 Hz, 2 H, isomer 1), 7.30 (d, J = 8.7 Hz, 2 H, isomer 
2), 7.01 (d, J = 8.4 Hz, 2 H, isomer 1), 7.00 (d, J = 8.4 Hz, 2 H, isomer 2), 6.82 (d, J = 8.5 
Hz, 2 H, isomer 1), 6.68-6.58 (m, 6 H), 6.50 (d, J = 8.5 Hz, 2 H), 6.26 (d, J = 8.5 Hz, 2 H), 
3.75 (s, 2 H, isomer 1), 3.60 (s, 2 H, isomer 2), 2.61-2.52 (m, 4 H), 0.95-0.88 (m, 6 H); 13C 
NMR (75 MHz, methanol-d4) δ 177.1, 152.5, 148.6, 148.0, 147.0, 143.1, 139.3, 136.3, 
133.7, 133.2, 133.1, 132.1, 131.5, 124.1, 117.4, 117.2, 113.4, 112.9, 29.6, 14.0; ESIMS m/z 
417 (MH+); HRESIMS m/z calcd for C24H25N4O3 (MH+) 417.1927, found 417.1935; 
HPLC purity, 96.48% (90% MeOH, 10% H2O).
5.1.22 1-(1-Phenylpropylidene)hydrazine (19).34—A 98% hydrazine monohydrate 
solution (2 mL, 40 mmol) was added to propiophenone (18, 2.68 g, 20 mmol) in EtOH (15 
mL). The mixture was heated to reflux for 2 h. After cooling to room temperature, the 
mixture was partitioned between CH2Cl2 and H2O. The aqueous layer was extracted with 
CH2Cl2 (30 mL X 3). The organic layers were combined, dried, concentrated in vacuo and 
purified by column chromatography (hexane: EtOAc = 5: 1) to afford the product 19 as 
yellowish solid (2.60 g, 88% yield): mp 52–53 °C (lit.34 mp 55–57 °C).
5.1.23 1-(1,1-Dibromobut-1-en-2-yl)benzene (20)27—A 28% aqueous solution of 
ammonia (1 mL) and CuCl (29.7 mg, 0.3 mmol) were added to a solution of 1-(1-
phenylpropylidene)hydrazine 19 (444 mg, 3.0 mmol) in DMSO (3 mL). Then CBr4 (2.98 g, 
9 mmol) in DMSO (5 mL) was added dropwise. The reaction mixture was stirred at room 
temperature for 16 h and quenched with H2O (30 mL) and extracted with CH2Cl2 (20 mL X 
3). After being dried over Na2SO4, the CH2Cl2 was evaporated and the residue was purified 
by column chromatography (hexane) to afford the product 12 as a light brown oil (607 mg, 
70% yield). 1H NMR (400 MHz, CDCl3) δ 7.39-7.30 (m, 3 H), 7.19-7.16 (m, 2 H), 2.61 (q, 
J = 7.6 Hz, 2 H), 0.98 (t, J = 7.6 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 148.9, 140.9, 
128.4, 127.9, 127.7, 87.5, 32.8, 11.4; CIMS m/z 290 (MH+).
5.1.24 4-(1-(4-Hydroxyphenyl)-2-phenylbut-1-enyl)phenol (13)—A solution of 1-
(1,1-dibromobut-1-en-2-yl)benzene 20 (288 mg, 1.0 mmol), 4-hydroxyphenylboronic acid 
(552 mg, 4.0 mmol), PdCl2(PPh3)2 (70 mg, 0.1 mmol), and Na2CO3 (318 mg, 3.0 mmol) in 
THF-H2O (4:1, 15 mL) was heated to 70 °C under Ar2 for 18 h. After cooling to room 
temperature, EtOAc (15 mL) and H2O (10 mL) were poured into the reaction mixture. The 
aqueous layer was extracted with EtOAc (20 mL X 3). The combined organic layers were 
washed with water and dried, concentrated in vacuo and purified by silica gel flash column 
chromatography (hexane: EtOAc = 4:1) to afford the product 13 as white solid (164 mg, 
52% yield): mp 198–200 °C. 1H NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1 H), 9.15 (s, 1 H), 
7.18 (t, J = 7.6 Hz, 2 H), 7.10 (t, J = 7.6 Hz, 3 H), 6.98 (d, J = 8.8 Hz, 2 H), 6.75 (d, J = 8.4 
Hz, 2 H), 6.60 (d, J = 8.4 Hz, 2 H), 6.40 (d, J = 8.8 Hz, 2 H), 2.41 (q, J = 7.2 Hz, 2 H), 0.84 
(t, J = 7.2 Hz, 3 H); 13C NMR (100 MHz, DMSO-d6) δ 156.8, 155.9, 143.2, 140.1, 139.0, 
134.8, 134.6, 132.2, 130.9, 130.2, 128.6, 126.6, 115.7, 115.0, 29.3, 14.2; HRAPCIMS m/z 
calcd for C22H21O2 (MH+) 317.1542, found 317.1565.
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5.1.25 (E,Z)-2-(4-(1-(4-Hydroxyphenyl)-2-phenylbut-1-enyl)phenoxy)-acetamide 
(17)—The intermediate was prepared as previously described.18
5.1.26 (E,Z)-Norendoxifen—This compound was prepared as previously described.18
5.2 Inhibition of Recombinant Human Aromatase (CYP19) by Microsomal Incubations
These experiments were conducted as previously described.19
5.3 Binding Affinities for Recombinant Human ER-α and ER-β
The binding affinities were determined as previously described.19
5.4 Abilities of Compounds to Antagonize β-Estradiol-stimulated Progesterone Receptor 
(PGR) mRNA Expression in MCF-7 Cells
The assay was performed as previously described.19
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Acknowledgments
This research was supported by the Purdue University Center for Cancer Research and the Indiana University 
Center Joint Funding Award 206330, and by the Purdue Center for Cancer Research grant P30 CA023168.
Abbreviations
AIs aromatase inhibitors
ATAC arimidex, tamoxifen, alone or in combination
DMSO dimethyl sulphoxide
ER estrogen receptor
EtOAc ethyl acetate
EtOH ethanol
MeOH methanol
SAR structure-activity relationship
SERM selective estrogen receptor modulator
THF tetrahydrofuran
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Figure 1. 
Structures of the SERM tamoxifen (1) and its metabolites 4-hydroxytamoxifen (2), 
endoxifen (3), norendoxifen (4), and 4′-hydroxynorendoxifen (5), and an active synthetic 
imidazole analogue 6.
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Figure 2. 
Structures of the third generation AIs letrozole (7), anastrozole (8) and exemestane (9).
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Figure 3. 
Design strategy for hybrid AI/SERMs.
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Figure 4. 
Hypothetical molecular model of 12d bound in the active site of aromatase (PDB code 
3s7928).
Zhao et al. Page 19
Bioorg Med Chem. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
Hypothetical molecular model of 12d bound in the active site of ER-α (PDB code 3ert29).
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Figure 6. 
Abilities of compounds 16c, 16d, 12d, 12c, endoxifen, and (E,Z)-norendoxifen (1 μM) to 
antagonize β-estradiol (E2, 10 nM)-stimulated progesterone receptor (PGR) mRNA 
expression in MCF-7 cells. PGR mRNA expression levels relative to estradiol (100%): 16c 
(14.1%), 16b (16.3%), 16c (16.8%), 16d (19.6%), endoxifen (3.6%), (E,Z)-norendoxifen 
(21.5%). MCF-7 cells were preconditioned in charcoal-stripped FBS for 72 hours to remove 
the estrogens. The cells were treated with vehicle (1% methanol), 1 μM endoxifen or 1 μM 
test compound in the presence of 10 nM β-estradiol (E2) and 10 nM β-estradiol alone for 24 
hours. Total RNA was isolated from the cells and cDNA was prepared. The E2-stimulated 
PGR mRNA expression was quantified using a real-time Taqman® PCR assay.
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Scheme 1. 
Attempted Preparation of 12a through the McMurry Reaction.
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Scheme 2. 
Synthesis of 12a–d. Reagents and conditions: (a) N2H4·H2O, EtOH; (b) CBr4, CuCl, 
DMSO; (c) 4-(HO)PhB(OH)2 or 4-(H2N)PhB(OH)2, PdCl2(PPh3)2, Na2CO3, THF-H2O.
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Scheme 3. 
Synthesis of 15a–d. Reagents and conditions: (a) SnCl2, EtOH.
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Scheme 4. 
Synthesis of 16a–d. Reagents and conditions: (a) ICH2CONH2, acetone, K2CO3; (b) 
LiAlH4, AlCl3, THF.
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Scheme 5. 
Synthesis of (E,Z)-Norendoxifen through the Suzuki Coupling Reaction. Reagents and 
conditions: (a) N2H4·H2O, EtOH; (b) CBr4, CuCl, DMSO; (c) (HO)2BPh-4-OH, 
PdCl2(PPh3)2, Na2CO3, THF-H2O; (d) ICH2CONH2, acetone, K2CO3; (e) LiAlH4, AlCl3, 
THF.
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Table 1
Aromatase inhibitory activities and ER binding affinities of 12a–da,b,c
compd aromatase (IC50, nM, or percent 
inhibition)
ER-α (EC50, nM, or percent 
competition)
ER-β (EC50, nM, or percent 
competition)
12a 75% inhibition at 50 μM 19% competition at 100 μM 55% competition at 100 μM
12b 78% inhibition at 50 μM 40% competition at 100 μM 66% competition at 100 μM
12c 220.8 ± 42.2 212.9 ± 53.7 486.2 ± 239.5
12d 62.2 ± 7.8 72.1 ± 42.6 70.8 ± 5.2
13 24880 ± 7.8 80% competition at 100 μM 306.9 ± 106.4
(E,Z)-norendoxifen 102.2 ± 32.7 26.9 ± 4.8 35.2 ± 16.8
(E)-norendoxifen 76.8 ± 33.3 58.7 ± 1.0 78.5 ± 57.3
(Z)-norendoxifen 1029 ± 318 17.0 ± 1.9 27.5 ± 14.3
Estradiol 5.7 5.6
a
IC50 values were determined for compounds exhibiting inhibition values higher than 90%.
b
Percent aromatase inhibition was determined at the concentration of 50000 nM for each compound.
c
Percent ER competition was determined at the concentration of 100000 nM for each compound.
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Table 2
Aromatase inhibitory activities and ER binding affinities of 15a–da,b
compd aromatase (IC50, nM) ER-α (EC50, nM, or percent competition) ER-β (EC50, nM, or percent competition)
15a 230.0 ± 11.4 11036 ± 827 857 ± 389
15b 8.8 ± 1.6 1711 ± 630 1263 ± 424
15c 177.1 ± 20.2 31% competition at 100 μM 77% competition at 100 μM
15d 13.4 ± 3.0 25% competition at 100 μM 76% competition at 100 μM
Estradiol 5.7 5.6
a
IC50 values were determined for compounds exhibiting inhibition values higher than 90%.
b
Percent ER competition was determined at the concentration of 100000 nM for each compound.
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Table 3
Aromatase inhibitory activities and ER binding affinities of 16a–da,b,c
compd aromatase (IC50, nM, or percent 
inhibition
ER-α (EC50, nM, or percent 
competition)
ER-β (EC50, nM, or percent 
competition)
16a 9724 ± 224 0% competition at 100 μM 0% competition at 100 μM
16b 76% inhibition at 50 μM 0% competition at 100 μM 0% competition at 100 μM
16c 645.3 ± 246.4 164.1 ± 96.9 218.4 ± 102.7
16d 286.9 ± 31.8 451.2 ± 201.2 346.4 ± 115.3
17 9257 ± 195 57% competition at 100 μM 71% competition at 100 μM
Estradiol 5.7 5.6
a
IC50 values were determined for compounds exhibiting inhibition values higher than 90%.
b
Percent aromatase inhibition was determined at the concentration of 50000 nM for each compound.
c
Percent ER competition was determined at the concentration of 100000 nM for each compound.
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